Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): Recent developments

被引：16

作者：

Simon, GR

Bunn, PA

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA

[2] Univ Colorado, Hlth Sci Ctr, Denver, CO USA

来源：

CANCER INVESTIGATION | 2003年 / 21卷 / 01期

关键词：

non-small cell lung cancer; chemotherapy; radiaion therapy; cisplatin; carboplatin; paclitaxel; docetaxel; gemcitabine; vinorelbine;

D O I：

10.1081/CNV-120005919

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Taxanes, paclitaxel. and docetaxel have become the cornerstone of both first-line and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Recently, several pivotal phase III randomized trials have been published. These studies and phase II trials will be discussed. Additionally, studies utilizing a taxane and radiation therapy for resectable and locally advanced NSCLC will be outlined. The article will end with a discussion on newer strategies being currently explored to improve survival in advanced NSCLC.

引用

页码：87 / 104

页数：18

共 58 条

[11] ASSEMBLY OF PURIFIED GDP TUBULIN INTO MICROTUBULES INDUCED BY TAXOL AND TAXOTERE - REVERSIBILITY, LIGAND STOICHIOMETRY, AND COMPETITION
DIAZ, JF
ANDREU, JM
[J]. BIOCHEMISTRY, 1993, 32 (11) : 2747 - 2755
[12] Phase II study of Docetaxel and Cisplatin in a circadian timing as first line chemotherapy (CT) in advanced non small cell lung cancer (NSCLC)
Faderl, B
von Pawel, J
Wagner, H
Krauss, C
Achterrath, W
[J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
[13] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
Fossella, FV
DeVore, R
Kerr, RN
Crawford, J
Natale, RR
Dunphy, F
Kalman, L
Miller, V
Lee, JS
Moore, M
Gandara, D
Karp, D
Vokes, E
Kris, M
Kim, Y
Gamza, F
Hammershaimb, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2354 - 2362
[14] Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
Furuse, K
Fukuoka, M
Kawahara, M
Nishikawa, H
Takada, Y
Kudoh, S
Katagami, N
Ariyoshi, Y
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2692 - 2699
[15] GANDARA DR, 2000, P AN M AM SOC CLIN, V19, pA490
[16] GASPAR L, 2001, P AN M AM SOC CLIN, V20, pA315
[17] Randomized Pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitexel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
Gatzemeier, U
Rosell, R
Betticher, D
Keppler, U
Macha, HN
Pirker, R
Berthet, P
Breau, JL
Bogaerts, J
Gallant, G
[J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S246 - S246
[18] Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
Gatzemeier, U
von Pawel, J
Gottfried, M
ten Velde, GPM
Mattson, K
DeMarinis, F
Harper, P
Salvati, F
Robinet, G
Lucenti, A
Bogaerts, J
Gallant, G
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3390 - 3399
[19] Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
Georgoulias, V
Kouroussis, C
Androulakis, N
Kakolyris, S
Dimopoulos, MA
Papadakis, E
Bouros, D
Apostolopoulou, F
Papadimitriou, C
Agelidou, A
Hatzakis, K
Kalbakis, K
Kotsakis, A
Vardakis, N
Vlachonicolis, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 914 - 920
[20] GEORGOULIAS V, 1999, P AN M AM SOC CLIN, V18, pA461

← 1 2 3 4 5 6 →